Suppository treatment in ulcerative proctitis | Zendy

Yingjie Si | Zendy; LanJun Shao | Zendy; Shanqing Gao | Zendy; Hong-Zhu Wen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Suppository treatment in ulcerative proctitis

Author(s) -

Yingjie Si,

LanJun Shao,

Shanqing Gao,

Hong-Zhu Wen

Publication year - 2021

Publication title -

european journal of inflammation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.219

H-Index - 20

eISSN - 2058-7392

pISSN - 1721-727X

DOI - 10.1177/20587392211015108

Subject(s) - suppository , ulcerative colitis , medicine , adverse effect , budesonide , tofacitinib , gastroenterology , tacrolimus , pharmacology , corticosteroid , disease , transplantation , rheumatoid arthritis

Ulcerative proctitis (UP) is a common form of ulcerative colitis (UC), the number of patients with UP is increasing. Suppository treatment containing mesalamine is usually the first-line choice for mild to moderate UP, here, we review the publications on mesalamine suppository in UP, to better understand its dosage, duration of therapy and adverse events in both induction and maintenance phases. We also review articles on budesonide, beclomethasone, tacrolimus, herbal medicine and acetarsol suppositories in UP, to present therapeutic strategies for patients with UP refractory to mesalamine suppository.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research